Citi raised the firm’s price target on Cogent Biosciences (COGT) to $22 from $15 and keeps a Buy rating on the shares. The firm says that following the results for bezuclastinib in non-advanced systemic mastocytosis, the drug is being viewed as upgrade over Blueprint Medicines’ (BPMC) Ayvakit. Citi sees more data catalysts for Cogent.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences: Buy Rating Affirmed Amid Promising Trials and Strategic Advantages
- Cogent Biosciences Raises $230M Through Stock Sale
- Cogent Biosciences 22.2M share Spot Secondary priced at $9.00
- Cogent Biosciences $150M Spot Secondary; price range $9.00-$9.50
- Cogent Biosciences offers to sell $150M in common stock